Preclinical Evaluation of
89Zr-IAB22M2C PET imaging
CD8 T cell
GUCY2C bispecific antibody
Immuno-oncology
Journal
Molecular imaging and biology
ISSN: 1860-2002
Titre abrégé: Mol Imaging Biol
Pays: United States
ID NLM: 101125610
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
05
03
2021
accepted:
03
06
2021
revised:
19
05
2021
pubmed:
19
6
2021
medline:
5
4
2022
entrez:
18
6
2021
Statut:
ppublish
Résumé
A sensitive and specific imaging biomarker to monitor immune activation and quantify pharmacodynamic responses would be useful for development of immunomodulating anti-cancer agents. PF-07062119 is a T cell engaging bispecific antibody that binds to CD3 and guanylyl cyclase C, a protein that is over-expressed by colorectal cancers. Here, we used NOD SCID gamma mice bearing human CRC LS1034 tumors were treated with four different doses of PF-07062119, or a non-targeted CD3 BsAb control, and imaged with The results demonstrated substantial mean uptake of Immune-imaging technologies for quantitative cellular measures would be a valuable biomarker in immunotherapeutic clinical development. We demonstrated a qualification of
Identifiants
pubmed: 34143379
doi: 10.1007/s11307-021-01621-0
pii: 10.1007/s11307-021-01621-0
pmc: PMC8578158
doi:
Substances chimiques
Biomarkers
0
Zirconium
C6V6S92N3C
Receptors, Enterotoxin
EC 4.6.1.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
941-951Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
© 2021. The Author(s).
Références
Hum Pathol. 2005 Feb;36(2):170-9
pubmed: 15754294
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
pubmed: 19474385
Mol Immunol. 2015 Oct;67(2 Pt A):142-52
pubmed: 25934435
J Comput Assist Tomogr. 1979 Jun;3(3):299-308
pubmed: 438372
Eur J Nucl Med Mol Imaging. 2019 Feb;46(2):489-500
pubmed: 30456475
Nat Rev Drug Discov. 2018 Nov 28;17(12):854-855
pubmed: 30482962
Am J Cancer Res. 2019 Aug 01;9(8):1546-1553
pubmed: 31497342
PLoS One. 2017 Dec 19;12(12):e0189953
pubmed: 29261789
Eur J Cancer. 2016 Jul;62:132-7
pubmed: 27189322
Nat Commun. 2017 Sep 21;8(1):647
pubmed: 28935898
Theranostics. 2019 Oct 18;9(26):8221-8238
pubmed: 31754392
Crit Rev Oncol Hematol. 2014 Dec;92(3):153-65
pubmed: 25195094
J Nucl Med. 2018 Mar;59(3):529-535
pubmed: 29025984
J Clin Invest. 2019 Feb 1;129(2):616-630
pubmed: 30457978
Oncotarget. 2017 Jun 27;8(26):41932-41946
pubmed: 28410210
J Immunol. 2011 Jul 15;187(2):654-63
pubmed: 21677135
Cancer Res. 2017 May 1;77(9):2318-2327
pubmed: 28461564
J Immunother Cancer. 2019 Nov 28;7(1):328
pubmed: 31779705
Nat Rev Cancer. 2016 May;16(5):275-87
pubmed: 27079802
Semin Nucl Med. 2017 Sep;47(5):454-460
pubmed: 28826520
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32238470
Q J Nucl Med Mol Imaging. 2014 Sep;58(3):237-57
pubmed: 25265246
Mol Imaging Biol. 2011 Oct;13(5):812-8
pubmed: 20838911
Cancer Res. 2020 Jul 1;80(13):2903-2913
pubmed: 32409308
J Nucl Med. 2020 May;61(5):641-642
pubmed: 32086241
Hum Pathol. 2019 May;87:103-114
pubmed: 30716341
J Nucl Med. 2020 Sep;61(9):1355-1360
pubmed: 32111688
J Nucl Med. 2007 Jun;48(6):932-45
pubmed: 17504879
Am Soc Clin Oncol Educ Book. 2019 Jan;39:147-164
pubmed: 31099674
Proc Natl Acad Sci U S A. 2015 Nov 24;112(47):E6506-14
pubmed: 26604307
J Nucl Med. 2020 Apr;61(4):512-519
pubmed: 31586002
Clin Cancer Res. 2018 Oct 15;24(20):4976-4987
pubmed: 29967252
Cold Spring Harb Perspect Med. 2017 Jul 5;7(7):
pubmed: 28213438
Cancer Res. 2019 Jul 1;79(13):3455-3465
pubmed: 31064845
Semin Oncol. 2011 Feb;38(1):55-69
pubmed: 21362516
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Nucl Med. 2020 Jul;61(7):943-950
pubmed: 32444375
Proc Natl Acad Sci U S A. 2014 Jan 21;111(3):1108-13
pubmed: 24390540
Clin Cancer Res. 2019 Feb 15;25(4):1196-1205
pubmed: 30327313
Clin Cancer Res. 2020 May 1;26(9):2188-2202
pubmed: 31996389
J Comput Assist Tomogr. 1984 Jun;8(3):514-22
pubmed: 6609942
Cancer Res. 2017 Jun 1;77(11):2893-2902
pubmed: 28572504